ClinicalTrials.gg
Status unknownNCT04738630Updated Feb 4, 2021

Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

A Phase 2 interventional study of HX008 in Bladder Cancer, sponsored by Taizhou Hanzhong biomedical co. LTD. Status unknown at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-04.

Sponsored by Taizhou Hanzhong biomedical co. LTD · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2020, registered Jan 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 194 studies in Urinary Bladder Neoplasms with a site in China — 102 open to participants now, 119 under way, 17 of them phase 3. Urinary Bladder Neoplasms · China.

Planned enrollment
53rd of 141
110 · median 75
Started
2020
with 10 others
Phase 2
40 of 194
22 open now
Registered
51st of 194
by date

Among the 194 studies in Urinary Bladder Neoplasms with a site in China, this one is the 53rd largest by planned enrollment of the 141 interventional ones that give a count, is one of 11 that started in 2020, is one of 40 in phase 2, and was the 51st registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

102 of the 194 studies in Urinary Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Urinary Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with BCG-unresponsive non-muscle invasive bladder cancer.

03

Conditions studied

  • Bladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be willing and able to provide written for the trial.
  • Age ≥ 18 years old, male or female.
  • Predominant histologic component (> 50%) must be urothelial (transitional cell) carcinoma.
  • Has a performance status of 0 or 1 on the (ECOG) Performance Score.
  • -confirmed diagnosis of high risk non-muscle invasive bladder cancer (T1, high grade Ta and/or carcinoma in situ [CIS]).
  • BCG-unresponsive high risk non-muscle-invasive bladder cancer, BCG-unresponsive disease as defined as: (a) Persistent or recurrent CIS (+/- recurrent Ta/T1 disease) within 9 months of receiving adequate BCG (at least five of six doses doses of an initial induction course plus either at least two of three doses of maintenance therapy or at least two of six doses of a second induction course); or (b) Recurrent high-grade Ta/T1 disease within 9 months of completion of adequate BCG (at least five of six doses of an initial induction course plus either at least two of three doses of maintenance therapy or at least two of six doses of a second induction course).
  • Patients must be deemed unfit for radical cystectomy by the treating physician or refuse radical cystectomy.
  • All visible tumor must be completely resected 60 days prior to the first dose of trial treatment. Patients with T1 tumors must undergo a re-staging transurethral resection of bladder tumor (TURBT) within 6 weeks after initial TURBT, and re-staging TURBT must be 60 days prior to the first dose of trial treatment.
  • All patients must have had a cystoscopy without papillary tumor and negative urinary cytology within 21 days prior to the first dose of trial treatment (positive cytology is allowed in patients with CIS component). A cystoscopy is not needed if the TURBT falls within 21 days of prior to the first dose of trial treatment.
  • Patients must have had imaging with X-ray for chest, computed tomography (CT) or magnetic resonance imaging (MRI) for abdomen/pelvis within 90 days prior to the first dose of trial treatment demonstrating no evidence of .
  • Willing to provide tissue specimens.
  • Has adequate organ function as defined in the protocol.
  • Male subjects must agree to use effective during treatment and for at least 120 days after the last treatment.
  • Women of childbearing age must have a negative pregnancy test within 72 hours before the first dose of trial treatment, and agree to use effective contraceptives during treatment and for at least 120 days after the last treatment.

Exclusion criteria

Exclusion Criteria:

  • Muscle-invasive or urothelial carcinoma.
  • Concurrent extra-vesical (i.e., urethra, ureter, or renal pelvis) non-muscle invasive transitional cell carcinoma of the urothelium.
  • Patients who had a malignant tumor other than urothelial carcinoma of the bladder within the first 5 years of enrolment. The following can be included: a. low-risk localized prostate cancer (staging ≤ T2B, Gleason score ≤7, PSA≤20ng/mL, no recurrence after treatment (as determined by PSA level)); b. low-risk prostate cancer (T1/ T2A, Gleason score ≤7, and PSA≤10ng/mL) who were not treated and under observation; c. patients with very low risk metastasis or death of malignant tumor (5-year metastasis or death risk\< 5%), showed no recurrence after standard treatment, such as cervical cancer in situ, basal or squamous cell skin cancer, etc.
  • Has received prior therapy with an , or anti-PD-L1, or anti-CTLA-4, or anti-4-1BB agents.
  • Has received systemic chemotherapy or immunotherapy, or radiation therapy for bladder cancer.
  • Patients with active disease that has required systemic treatment in past 2 years.
  • Has received a major surgery within 4 weeks prior to the first dose of trial treatment.
  • Has a history of testing positive for (HIV), or known acquired immunodeficiency syndrome (AIDS), or stem cell transplantation or organ transplantation.
  • Patients with active chronic or active . Patients with non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA below the threshold of the test standard of each center), and cured hepatitis C can be enrolled.
  • Has received system treatment with (dose >10mg/day prednison or other therapeutic hormones) within 2 weeks prior to the first dose of trial treatment.
  • Has a history of active tuberculosis.
  • Has a history or current interstitial pneumonia, or current non--infectious pneumonitis.
  • Has uncontrolled systemic disease, such as diabetes or hypertension.
  • Has cardiac dysfunction (grade III-IV according to ) and significant pulmonary disease (such as shortness of breath at rest or minor activity or the need for oxygen for any reason) prior to the first dose of trial treatment.
  • Patients with other disease, or metabolic disorder, or abnormal physical examination or laboratory test, or anticipated to cause complications with trial treatment.
  • Has a severe infection prior to the first dose of trial treatment.
  • Has a history of severe allergic reaction to any other monoclonal antibodies.
  • Has participated in other anticancer drug clinical trials within 4 weeks.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.
  • Has received a within 30 days prior to the first dose of trial treatment.
  • According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Experimental: HX008

    Participants will receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)

    Drug: HX008

Interventions

  • DrugHX008

    200 mg administered as IV infusion on Day 1 of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Complete response (CR) rate

    Time frame: up to approximately 24 months

  2. Event-free survival (EFS)

    Time frame: up to approximately 36 months

Secondary outcomes

  1. Duration of response (DOR)

    Time frame: up to approximately 36 months

  2. Event-free survival (EFS) in the Ta/T1 subset

    Time frame: up to approximately 36 months

  3. Progression-free survival (PFS)

    Time frame: up to approximately 36 months

  4. Recurrence free survival (RFS)

    Time frame: up to approximately 36 months

  5. Overall survival (OS)

    Time frame: up to approximately 36 months

  6. Cystectomy-free survival

    Time frame: up to approximately 36 months

07

Study locations

5 of 5 sites recruiting
  • Union Hospital Affiliated to Tongji Medical College, Huazhong University of science and technology
    Wuhan, Hubei 430022, China
    Recruiting
    • Xiaoping Zhang · Contact
  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology
    Wuhan, Hubei 430030, China
    Recruiting
    • Zhiquan Hu · Contact
  • Hunan Cancer Hospital
    Changsha, Hunan 410000, China
    Recruiting
    • Weiqing Han · Contact
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
    Recruiting
    • Dingwei Ye · Contact
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Sichuan 400016, China
    Recruiting
    • Xin Gou · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Dec 2022, 26 months after the start.

Of 39 industry-sponsored phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's planned 26 months is below that.

Counting every sponsor, half of 194 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2021
First posted
Feb 4, 2021
StartActual
Sep 25, 2020
Primary completionEst.
Dec 1, 2022
CompletionEst.
Dec 1, 2023
Last update
Feb 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04738630
Lead sponsor
Taizhou Hanzhong biomedical co. LTD
Responsible party
Sponsor
First posted
Feb 4, 2021
Start date
Sep 25, 2020
Primary completion
Dec 1, 2022 (estimated)
Completion
Dec 1, 2023 (estimated)
Last update
Feb 4, 2021

Study contacts

Dingwei Ye
Contact
dwyeli@163.com
34778299

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pucotenlimab

Start the discussion